What is true about country of origin for pharmaceuticals?

• A. FDA considers country of origin where the drug is manufactured
• B. FDA considers country of origin where the active ingredient was made
• C. CBP considers country of origin where the drug is manufactured
• D. CBP considers country of origin where the active ingredient was made

Answer: (B)

The key idea is that FDA regulatory considerations for a pharmaceutical’s country of origin focus on where the active ingredient was produced. The active ingredient is the component that defines the drug’s therapeutic effect and critical quality attributes, so regulators track its source to assess risk, integrity of the supply chain, and compliance with manufacturing controls. Even if the finished dosage form is manufactured in a different country, the origin of the active ingredient determines the regulatory origin used by FDA. This helps regulators pinpoint where potential quality issues could originate and ensures appropriate oversight across the supply chain.